The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
DEA & DOJ Officially Submit Proposal for Cannabis Rescheduling, Setting Comment Period in Motion
The Drug Enforcement Administration (DEA) published its formal proposal for cannabis rescheduling, officially putting what is set to be the most meaningful overhaul of cannabis regulation in 50-years into motion.
Tuesday’s (May 21, 2024) publication of the proposal means that the 60-day comment period is now open, giving commenters until July 22 to submit their comments electronically. Interested parties may also file a request for a hearing on or before June 20.
In its proposal, the DEA says that the Attorney General has determined that cannabis does not appear to meet the elements of a Schedule II drug, including high potential for abuse and the likelihood of severe physiological or physical dependence.
It also notes that synthetically produced cannabis would not be included in the reclassification, which is outside of the Controlled Substances Act’s (CSA) definition, and will therefore remain a Schedule I substance.
Comments are now being sought from ‘all interested persons’, and are expected to include the general public, stakeholders in the medical and scientific community, legal and regulatory experts, industry representatives, advocacy groups, and government agencies.
Specifically, the proposal calls for comments relating to the economic analysis of the proposed changes and encourages commenters to provide detailed descriptions, especially concerning the impact on small entities, and to support their comments with empirical data.
In this vein, the DOJ says it ‘acknowledges that there may be large impacts related to Federal taxes and research and development investment for the pharmaceutical industry, among other things.’
Furthermore, it states that the Attorney General, Merick Garland, must consider compliance with international treaty obligations, including the Single Convention, which requires signatories to ‘maintain various provisions related to the drugs’ covered by the treaty.
While no prospective timeline was given for how long the comments will take to consider, or whether a final hearing will take place, sources speaking to Business of Cannabis have suggested the change could be finalised by Q1 2025.
Could Rescheduling Finally Bring Institutional Investment in to Cannabis?
Next PostAkanda Implements 2nd Stock Split Amid Debt Woes, DanCann Pharma Earnings Fall Due to Strategy Change, & More From Celadon
Ben Stevens
Editor and Journalist with more than seven years experience reporting on business and financial sectors.
Related Posts
Related Posts
Illinois’ Cannabis Market Hits Record $2bn in Sales
Illinois’ cannabis industry hit $2 billion in total sales in 2024, generating $490 million in tax revenue, marking another year...
Trump’s DEA Revolving Door: 4th Administrator in as Many Months Rings Alarm Bells for Cannabis Industry
The fourth head of the Drug Enforcement Administration (DEA) in as many months has been given the green light by...
Republican Senators Introduce Bill to Block Cannabis 280E Tax Relief Even if Cannabis Is Rescheduled
Arizona Attempts to Force Funding of Medical Cannabis Research Through Sales Taxes
Hawaii House Shelves Recreational Cannabis Bill in Stunning Reversal
New York Bill Seeks to Decriminalize Drug Possession, Establish Reform Task Force
CONNECT
Related Posts
Related Posts
Illinois’ Cannabis Market Hits Record $2bn in Sales
Illinois’ cannabis industry hit $2 billion in total sales in 2024, generating $490 million in tax revenue, marking another year...
Trump’s DEA Revolving Door: 4th Administrator in as Many Months Rings Alarm Bells for Cannabis Industry
The fourth head of the Drug Enforcement Administration (DEA) in as many months has been given the green light by...
Republican Senators Introduce Bill to Block Cannabis 280E Tax Relief Even if Cannabis Is Rescheduled
As the cannabis rescheduling project hangs in the balance, two Republican senators are attempting to ensure that one of its...
Arizona Attempts to Force Funding of Medical Cannabis Research Through Sales Taxes
Arizona lawmakers are attempting to force the state’s Department of Health Services (DHS) to put millions of dollars towards medical...
Hawaii House Shelves Recreational Cannabis Bill in Stunning Reversal
Less than 48 hours after Hawaii lawmakers appeared poised to legalize recreational cannabis, the state’s House of Representatives unexpectedly slammed...
Recent Posts
Related Posts
Republican Senators Introduce Bill to Block Cannabis 280E Tax Relief Even if Cannabis Is Rescheduled
As the cannabis rescheduling project hangs in the balance, two Republican senators are attempting to ensure that one of its...
Oregon’s Oversupply Issues Reach Breaking Point as Prices Reach All-Time Low
Oregon’s cannabis industry is in crisis as a record-breaking harvest in 2024 exacerbates an already severe oversupply problem.Â
Difficult Start to the Year for Cannabis Stocks as Uncertainty Reigns
A new US administration, China’s AI upset, and now a looming trade war have played havoc with the stock market...
Ohio’s Recreational Cannabis Market Sees Price Compression Amid New Efforts to Roll Back Laws
Just five months after launching, Ohio's adult-use cannabis market has reached $242.2 million in sales, largely in line with industry...
CRS Research Says Cannabis Rescheduling Future ‘Unclear’ as Legal Challenges Emerge
This week has seen another frenetic torrent of executive orders issued by the newly inaugurated President Trump, causing chaos across...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags